Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

33.42USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$33.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,151,953
52-wk High
$42.15
52-wk Low
$27.50

MDCO.O

Chart for MDCO.O

About

The Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute... (more)

Overall

Beta: 0.54
Market Cap(Mil.): $2,610.88
Shares Outstanding(Mil.): 70.79
Dividend: --
Yield (%): --

Financials

  MDCO.O Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -0.83 -- --
ROI: -3.13 15.56 14.95
ROE: -5.70 16.69 16.29

BRIEF-Mylan signs sub-license agreement with the Medicines Patent Pool to produce and market DAKLINZA tablets to 112 countries

* Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to Hepatitis C treatment in developing countries

Nov 28 2016

BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran

* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)

Nov 15 2016

Long-lasting cholesterol lowering seen with Medicines Co drug: study

NEW ORLEANS A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing.

Nov 15 2016

Long-lasting cholesterol lowering seen with Medicines Co drug -study

NEW ORLEANS, Nov 15 A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing.

Nov 15 2016

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months

Nov 13 2016

BRIEF-Medicines Co says discontinues development of MDCO-216

* Medicines Co says discontinues development of MDCO-216, its investigational cholesterol efflux promoter

Nov 07 2016

UPDATE 4-Pfizer cholesterol drug fizzles, hitting shares

Nov 1 Pfizer Inc scrapped its high-profile cholesterol fighter after its effectiveness waned over time in large clinical trials, sending its shares 2 percent lower and prompting the company to trim its 2016 earnings forecast.

Nov 01 2016

BRIEF-Medicines Q3 revenue $37.6 mln versus I/B/E/S view $37.3 mln

* The medicines company reports third-quarter 2016 financial results

Oct 26 2016

BRIEF-China National Accord Medicines to buy 30 pct stake in unit at 3.5 mln yuan

* Says it plans to acquire 30 percent stake in its 70 percent owned unit, at price of 3.5 million yuan

Oct 24 2016

BRIEF-Medicines Co announces positive top-line results from day 90 interim analysis in ongoing Orion-1 Phase 2 study of PCSK9si

* Medicines company announces positive top-line results from day 90 interim analysis in ongoing orion-1 phase 2 study of pcsk9si

Oct 18 2016

Earnings vs. Estimates